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Abstract. New drugs for causal prophylaxis of malaria are needed. A proguan
il/sulfamethoxazole combination was investigated using a rhesus monkey model (Macaca
mulaiia infected with Plasmodium cynomolgi) to determine whether causal prophylaxis
could be achieved. When a five-day regimen of proguanil (40 mg/kg/day) combined with
sulfamethoxazole (100 mg/kg/day) was used, infection of all animals (6 of 6) was observed,
with an extended prepatent period (median 40 days). Two control animals became infected
on days 9 and 23 following sporozoite inoculation. Plasma concentrations indicated that
proguanil and sulfamethoxazole were adequately absorbed and metabolized to cycloguanil
and N4-acetylsulfamethoxazole, respectively. Analysis of liver biopsy specimens demon
strated that the drugs were present two days following sporozoite inoculation but were not
detectable one week later. Proguanil plus sulfamethoxazole does not eliminate exoerythro
cytic-stage parasites in the rhesus monkeyâ€”P. cynomolgi model.
Antifolates have been popular chemoprophylac
tic agents against malaria because of the infre
quency of side effects, low cost, and good com
pliance. Although resistance to single agents such
as pyrimethamine and proguanil has made antifol
ates ineffective in many areas, proguanil combi
nations are often recommended for causal prophy
laxis in areas of malaria drug resistance.'2
Proguanil plus sulfamethoxazole has recently been
shown to provide effective prophylactic protection
in human field trials, with marked synergy be
tween the components.34 The problem of relapsing
in Plasmodium vivax infections following the end
of doxcycline chemoprophylaxis (up to 30% in
fection within one month after ending doxycy
dine) was not seen with proguanil plus sulfame
thoxazole.5 It seemed possible that a proguanil
combination might have increased causal prophy
lactic activity against relapsing forms of malaria.
The only established primate model of causal
prophylaxis, Macaca mulatta infected with P. cy
nomolgi, was used to test this hypothesis. This
simian parasite is biologically related to P. vivax
in its relapse patterns and its response to standard
antimalarial drugs.6
MATERIALS AND METHODS
Animal experiments
The methods of Schmidt and others were used
for the M. mulaiiaâ€”P. cynomolgi model.â€•Malar
ia-naive rhesus monkeys of either sex weighing
between 2 and 5 kg were infected intravenously
with 0.5â€”1 x 10â€•P. cynomolgi sporozoites on
day 0. Proguanil (40 mg/kg/day) plus sulfame
thoxazole (100 mg/kg/day) was given daily on
days â€”2,â€”1, 0, + 1, and +2. Daily blood smears
were used to detect parasitemia until 100 days.
at which time negative blood smears were as
sessed to indicate successful prophylaxis. Un
treated control animals were used to insure the
infectivity of the sporozoites and estimate the
prepatent period.
Animals were housed as a closed colony in
double-screened, open-air ventilated animal
rooms. They were fed a standard monkey
chow, supplemented three times a week with
approximately 100 g of fresh fruit. Water was
freely available via automatic watering devices.
Animals were sedated intramuscularly with ke
tamine hydrochloride (5â€”10mg/kg) during na
sogastric administration of test drugs, liver bi
opsies. intravenous sporozoite injection, and
blood sample collections. Daily blood smears
were made without sedation from the margin of
the ear using sterile, disposable, pediatric skin
lancets. After the conclusion of each set of ex
periments, animals were cleared of any remain
ing parasites by the administration of chloro
quine and primaquine. Curative treatment was
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TABLE I
Summary of parasitemia data for Macaca mulatta
monkeys infected with Plasmodium cynomolgi fol
lowing multiple dosing with proguanil (PRO) plus
sulfamethoxazole (SMX)
stored at â€”70Â°Cuntil analysis. When testing
proguanil plus sulfamethoxazole, open liver bi
opsies were done on one control and three mon
keys that had received the drug combination on
day 2 postinfection and the remaining control
and three other monkeys that had received the
drug combination on day 9 postinfection. Liver
specimens were dissected to a wet weight of ap
proximately 250 mg and stored at â€”70Â°C.
Drug analysis
Plasma and liver concentrations of proguanil
and sulfamethoxazole and their principal metab
olites, cycloguanil and N4-acetylsulfamethoxa
zole, were measured by high-performance liquid
chromatography. The drugs were analyzed on a
Waters 840 chromatographic system (Millipore
Waters, Milford, MA) consisting of a Model 510
pump, Model U6K injector, and a Lambda-Max
Model 41 8 spectrophotometer. Chromatographic
separation of proguanil, cycloguanil, and the in
ternal standard chlorcycloguanil were performed
on a Spherisorb-5-Phenyl column (particle size
5 pm, 150 x 4.6 mm internal diameter; HPLC
Technology, Cheshire, UK). The mobile phase
consisted of methanol and water (29:7 1 v/v)
containing 5 mM low ultraviolet pentane-sulfon
ic acid (Millipore-Waters). Absorbance was
measured at 238 nm. The run time was less than
17.5 mm. Plasma samples (0.5 ml) containing
200 ng of chlorcycloguanil were prepared for
solid-phase extraction based on the method of
Taylor and others.7 The interassay and intraassay
coefficients of variation for both proguanil and
cycloguanil at 10 ng/ml were less than 10% (n
= 6). Liver samples were homogenized with an
equal volume of water and then ultrasonicated.
Liver suspensions (100 p1) were precipitated
with methanol (I ml), centrifuged, and the su
pernatant (1 ml) was subjected to solid-phase
extraction. The intraassay coefficients of va.ria
tion for proguanil and cycloguanil at 200 ng/100
p1 of liver suspension were 4.6% and 4.5%, re
spectively(n = 4).
Sulfamethoxazole, N4-acetylsulfamethoxazo
le, and the internal standard sulfalene were sep
arated on a Nova-Pak C I 8 column (particle size
4 p.m. 150 x 3.9 mm internal diameter; Milli
pore-Waters). The mobile phase consisted of
acetonitrile, water, and glacial acetic acid (18.5:
8 1:0.5, v/v/v). Absorbance was measured at 268
nm. The total run time was less than I 2 mm.
verified by consistently negative blood smears
for 100 days after the last treatment. Routine
preventive medicine and health assessment pro
cedures for all nonhuman primates in the col
ony included semiannual physical examinations
and tuberculin skin testing. This research was
conducted according to the principles enunci
ated in the Guidefor the Care and Use of Lab
oraiory Animals, Institute of Laboratory Ani
mal Research, National Research Council, NIH
Pub. No. 85-23, and applicable Federal laws
and regulations.
Drugs used included proguanil hydrochloride
(Paludrine@; Imperial Chemical Industries,
London, UK) and sulfamethoxazole (Ganitol@;
Roche Laboratories, Nutley, NJ). Tablets of
proguanil and sulfamethoxazole were crushed
to a fine powder using a mortar and pestle.
Drugs were individually weighed on an analyt
ical scale and maintained in a dry sealed vial
until just prior to administration. Drugs were
suspended in approximately 25 ml of distilled
water not more than 30 mm prior to adminis
tration. Placement of a size 8 french disposable
infant nasogastric feeding tube for drug admin
istration was verified by aspiration of gastric
contents through the tube or administration of
1â€”2ml of distilled water through the catheter
without subsequent coughing by the animal.
Following administration of the drugs, the feed
ing tube was flushed with 15 ml of distilled
water.
Blood samples for plasma drug determina
tions were obtained by venipuncture. After sep
aration from red blood cells, the plasma was
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FIGURE 1 . Minimum plasma concentration-time profiles (mean Â± SEM) of proguanil (PRO) and cycloguanil
(CYC) in rhesus monkeys (n = 6) infected with Plasmodium cvnomolgi. Arrows indicate the days of drug
administration.
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Plasma samples (200 p1) containing sulfalene (5
pg) were extracted using liquid-liquid extraction
at pH 5.6 based on the method of Edstein and
others for sulfadoxine analysis.â€• The interassay
and intraassay coefficients of variation for sul
famethoxazole (1 pg/200 p1) and N4-acetylsul
famethoxazole (0.25 pg/200 p.1) were less than
10% (n = 5). The detection limit was 20 ng/200
p.1 for both compounds. Liver samples were ho
mogenized in an equal volume of water, ultra
sonicated, and this suspension (200 p.1) was cx
tracted as described for plasma analysis. The
intraassay coefficients of variation for sulfame
thoxazole (0.5 p.g) and N4 acetylsulfamethoxa
zole (0. 125 jig) were 2.8% and 4.8%, respec
lively (n = 4).
RESULTS
Monkeys receiving proguanil plus sulfame
thoxazole for five days had their first detectable
parasitemia from 28 to 44 days (median 40) fol
lowing sporozoite inoculation (Table I). The
control monkeys who received no drug were
first parasitemic on days 9 and 23. There was no
obvious explanation for the unusually long pre
patent period in one of the control monkeys. The
usual prepatent period is eight days.9
The mean minimum plasma concentrations
(drawn just prior to the next dose) of proguanil
and cycloguanil are shown in Figure 1, which
demonstrates little or no drug present after day
5. A similar result is seen in Figure 2, which
shows the mean minimum plasma concentra
tions of sulfamethoxazole and N4-acetylsulfa
methoxazole. The liver concentrations (mean Â±
SD, n = 3) were 49.0 Â± 53.3 pg/gm for pro
guanil, 15.3 Â±4.7 pg/gm for cycloguanil, 15.9
Â±8.6 pg/gm for sulfamethoxazole, and 24.1 Â±
4.5 pg/gm for N4-acetylsulfamethoxazole. No
drug was detected in the livers of three drug
treated monkeys on day 9.
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FIGURE 2. Minimum plasma concentration-time profiles (mean Â± SEM) of sulfamethoxazole (SMX) and N4-
acetylsulfamethoxazole (NJSMX) in rhesus monkeys (n â€”6) infected with Plasmodium cynomolgi. Arrows
indicate the days of drug administration.
The pharmacologic data presented can be ap
proximately compared with previous studies in
humans. Proguanil has been reported to be ab
sorbed in humans and extensively metabolized
to cycloguanil, the triazine metabolite that is re
sponsible for the antimalarial activity.'2 Rhesus
monkeys appear to convert more proguanil to
cycloguanil than that found in humans with a
cycloguanil:proguanil concentration ratio greater
than I .0, compared with less than 1.0 in the ma
jority of humans.'3 The plasma elimination half
life of cycloguanil in rhesus monkeys (9.3 hr) is
shorter than that reported for humans (I 5. 1 hr).'4
The elimination half-life of sulfamethoxazole,
however, is similar in the rhesus monkey and
humans (9.2 hr versus I I .5 hr).'5 Both rhesus
monkeys and man metabolize sulfamethoxazole
to its principal N4-acetylated metabolite. The
five-day drug regimen used did not produce
measurable concentrations of drug at a time
when merozoites would be expected to be re
leased from the liver.
DISCUSSION
With the M. mulaiiaâ€”P. cvnomolgi model
used, we found no evidence of causal prophy
lactic activity using the combination of proguan
ii plus sulfamethoxazole. Previous work with 40
mg/kg of proguanil given for three days showed
a delay in the onset of patency (mean 36 days)
in three of three monkeys.9 The delayed prepa
tent period without protection may be explained
on the basis of two different populations of
schizonts in the exoerythrocytic cycle as previ
ously proposed by Bray.'Â° The synergistic com
bination of proguanil plus sulfamethoxazole was
inadequate to eliminate these tissue schizonts,
which do appear to have some antifolate sensi
tivity.â€• One possible explanation might be that
hypnozoites are not metabolically active enough
to be killed by antifolates. Thus, the primary tis
sue schizonts that multiply rapidly after infec
tion are killed, but the hypnozoites that undergo
multiplication later escape the antifolate action.
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The data presented here are in conflict with
some suggestions of causal prophylaxis from hu
man field trials.34 This could be explained by
the intrinsic differences in the human and mon
key tests. Plasmodium vivax may have a differ
ent drug sensitivity pattern than P. cynomolgi.
In field trials with humans, subjects are gener
ally exposed to small intermittent sporozoite in
oculations by mosquitoes during long periods of
continuous drug administration. The M. mulai
iaâ€”P.cynomolgi model uses a large artificial
sporozoite inoculation during a brief drug
course. Although the primate model system used
here was successful in screening 8-aminoquin
oline drugs similar to primaquine, it has limits
tions for the causal prophylactic assessment of
antifolates.6 Care must be taken when interpret
ing data from animal models of malaria infection
to classes of drug for which they were not orig
inally developed.
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